Although the scientific relevance on the aforementioned cardiovascular chance factor alterations by tirzepatide will probably be assessed within the planned cardiovascular outcome research SURPASS-CVOT ( "kind":"medical-demo","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Examinati